| abstract |
The present disclosure relates to iRNA agents, for example double-stranded iRNA agents, capable of inhibiting the expression of apolipoprotein C-III genes (also called APOC3, apoC-III, APOC-III and APO C-III), and to compositions including APOC3 iRNA agents. The iRNA agents for APOC3 disclosed herein can be conjugated to targeting ligands, including ligands that include N-acetyl-galactosamine, to facilitate delivery to cells, including hepatocytes. Also disclosed are pharmaceutical compositions that include one or more APOC3 iRNA agents, optionally with one or more additional therapeutic agents. Administration of APOC3 iRNA agents in vivo provides for inhibition of the expression of an APOC3 gene, and may result in lower triglyceride and / or cholesterol levels in the subject. The iRNA agents for APOC3 can be used in methods of treating APOC3-related diseases and disorders, including hypertriglyceridemia, cardiovascular disease, and other metabolism-related disorders and diseases. |